Stay updated with breaking news from Professor Abken. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- In its effort to develop effective cellular immunotherapies for cancer treatment, the Regensburg Center for Interventional Immunology (RCI) in...
Regensburg Center for Interventional Immunology adopts LUMICKS’ z-Movi® Cell Avidity Analyzer Amsterdam, the Netherlands – May 27, 2021 – In its effort to develop effective cellular immunotherapies for cancer treatment, the Regensburg Center for Interventional Immunology (RCI) in Germany has purchased LUMICKS’ z-Movi® Cell Avidity Analyzer. The placement highlights the promise of measuring cell avidity between immune cells and their tumor targets to improve the selection of chimeric antigen receptors (CARs) and accelerate the development of new CAR-T therapies. The new instrument h...